SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010; 116: 4422-4429.
  • 2
    Schiller GJ. When a gold standard is made of tin. Blood. 2010; 116: 4386-4387.
  • 3
    Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003; 21: 1167-1173.
  • 4
    Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010; 28: 549-555.
  • 5
    Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol. 2010; 28: 2389-2395.
  • 6
    Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008; 112: 1638-1645.
  • 7
    Cashen AF, Schiller GJ, O'Donnell DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010; 28: 556-561.
  • 8
    Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010; 107: 7473-7478.
  • 9
    Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21: 4642-4649.
  • 10
    Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 11
    Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 60: 163-170.
  • 12
    Cox DR. Regression models and life tables (with discussion). J R Statistical Soc B. 1972; 34: 187-220.
  • 13
    Estey EH. How I treat patients with AML. Blood. 2000; 96: 1670-1673.
  • 14
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. V. 1.2008. Available at: http://www.nccn.org/professionals/phsyician_gls/PDF/aml.pdf Accessed on August 1, 2011.
  • 15
    Juliusson G. Most 70- to 79-year old patients with acute myeloid leukemia do benefit from intensive treatment. Blood. 2011; 117: 3473.
  • 16
    Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006; 106: 1090-1098.
  • 17
    Malfuson JV, Etienne A, Turlure P, et al. Haematologica . 2008; 93: 1806-1813.
  • 18
    Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukemia: a web-based application for prediction of outcomes. Lancet. 2010; 376: 2000-2008.